Cogstate Limited (CGS.AX)
| Previous close | 1.4050 |
| Open | 1.4500 |
| Bid | 1.5000 x 925800 |
| Ask | 1.5950 x 411200 |
| Day's range | 1.4400 - 1.5950 |
| 52-week range | 1.3450 - 2.6800 |
| Volume | |
| Avg. volume | 157,218 |
| Market cap | 276.469M |
| Beta (5Y monthly) | -0.04 |
| PE ratio (TTM) | 21.85 |
| EPS (TTM) | 0.0730 |
| Earnings date | 23 Aug 2022 - 29 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.75 |
- GlobeNewswire
Cogstate Announces Formation of Scientific Advisory Board
Leading clinical and scientific experts in neurodegenerative diseases and pharmaceutical research will provide guidance to progress Cogstate’s strategyMelbourne, VIC, Australia; New Haven, CT, USA, June 14, 2022 (GLOBE NEWSWIRE) -- Cogstate (ASX.CGS) a leading neuroscience technology company, today announced the formation of a Scientific Advisory Board (SAB), comprising clinical and scientific experts in cognitive assessment and drug development. The SAB will work closely with the Cogstate scien
- Simply Wall St.
What Type Of Shareholders Own The Most Number of Cogstate Limited (ASX:CGS) Shares?
The big shareholder groups in Cogstate Limited ( ASX:CGS ) have power over the company. Large companies usually have...
- PR Newswire
Clario and Cogstate Expand Partnership to Deliver Leading Data Collection and Data Quality Programs for Neuroscience Clinical Trials
Clario, a technology company that delivers the leading endpoint solutions for decentralized (DCT), hybrid and site-based clinical trials, announced today, on World Clinical Trials Day, an expansion of its partnership with cognitive science company, Cogstate, to jointly provide data quality solutions to support the unique requirements of neuroscience assessments for therapeutic development.
